FLX Bio, Inc. is an immuno-oncology company focused on the discovery and development of orally-available, small molecule drugs to activate the immune system and eradicate cancer. Using our integrated immuno-oncology drug discovery platform, our small molecule compounds specifically target proteins and pathways important for regulatory T cells or myeloid cells within the tumor microenvironment. Our lead candidate, a best-in-class CCR4 inhibitor, entered Phase 1 studies in December 2017 and has the potential to be used alone or in combination with checkpoint inhibitors to treat a variety of cancers. We employ a precision medicine strategy for prospective patient selection in clinical studies, applying our robust computational and translational biology capabilities to identify key biomarkers related to improved clinical response and increased probability of clinical success.
Located in South San Francisco, Calif., and funded by leading investors, including The Column Group (TCG), Kleiner Perkins (KP), Topspin Partners, GV and Celgene Corporation, we have assembled a leadership team and advisory group with a proven track record of success and team of scientists with substantial knowledge and expertise in drug discovery and translational areas essential to execute on this approach.